Proactive: Race Oncology’s RC220 trial gets green light

Race Oncology Executive Chair Dr Peter Smith speak with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its Phase 1 clinical trial for RC220, a new formulation of bisantrene.

The full report can be accessed via this link.